MedTrace Logo

Lutein Iontophoresis in Intermediate AMD and Reticular Pseudodrusen - a Retrospective Study

NCT07420361 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 30

Last updated 2026-02-19

No results posted yet for this study

Summary

There is limited data available on the efficacy and safety of Transscleral Lutein Iontophoresis (TSLI) in patients with in-termediate age-related macular degeneration (iAMD) and reticular pseudodrusen (RPD).

This retrospective multicentre study evaluated the functional and morphological outcomes of TSLI in patients with stage 2 and stage 3 iAMD with RPD. Autofluorescence (AF), Optical Coherence Tomography (OCT), Best Corrected Visual Acuity (BCVA), Intraocular Pressure (IOP), Macular Sensitivity (MS) and adverse events, were recorded at baseline, 1 month and 3 months follow-up after treatment.

Conditions

  • Intermediate Age-Related Macular Degeneration With Reticular Pseudodrusen

Sponsors & Collaborators

  • Mario Damiano Toro

    lead OTHER

Eligibility

Min Age
55 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-08-01
Primary Completion
2024-08-31
Completion
2024-08-31

Countries

  • Italy

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07420361 on ClinicalTrials.gov